The United Kingdom and the United States have hammered out a important commercial pact that will preserve no levies on British drug exports going into the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost funding on drugs through the public health system. This move guarantees that duties on these key goods will be held at nothing for a duration of 36 months.
This development is in response to previous statements to dramatically increase tariffs on patented pharmaceutical imports, with potential rates discussed up to one hundred percent.
"This agreement between the United Kingdom strengthens the worldwide climate for new treatments and brings much-needed balance to American-British pharmaceutical trade," an announcement noted.
Economic Significance
Medicines are one of the the United Kingdom's biggest exports to the US, which is clearly the biggest market for leading British pharmaceutical firms.
Export figures reveal that in the one-year period prior to last September, the UK shipped medicines totaling £11.1bn to the US. This amount made up 17.4% of total UK exports in that timeframe.
"This agreement safeguards work, increases capital expenditure and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Key British Pledges
The pact includes several key commitments from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double total public funding on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be restricted at 15%. In the past, rebates topped 20%.
Broader Context
This agreement follows a protracted dispute between the sector and the ministers over spending levels and regulatory access.
These tensions were exacerbated by claims that US customers were paying several times more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or scrapped, while multi-billion-dollar investments have been announced toward US facilities.
One official publicly accepted that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had decreased as a percentage of its resources over the past decade.
